Incanthera Plc · AQUIS:INC
Incanthera — H1 2021 Earnings Presentation
13 slides from Incanthera's earnings presentation, Dec 8, 2020
Slide 1: Interim Results for the six months ended 30 September 2020
Interim Results for the six months ended 30 September 2020 8 December 2020 Novel Cancer Medicines through Targeted Technologies
Slide 2: Interim results for the six months ended 30 September 2020
Incanthera plc (AQSE; INC) Interim results for the six months ended 30 September 2020 Novel Cancer Medicines through Targeted Technology 2 Acquire, Prepare, Commercialise
Slide 3: The Presenting Team
The Presenting Team Tim McCarthy Simon Ward Chairman (Board) CEO (Board) CEO and CFO of public and Founder of Incanthera, former private biotech & healthcare founder, CEO and CSO of companies during 40 year private and public specialist international career. biotech & healthcare Non-Executive Chairm
Slide 4: Highlights
Highlights Successful Sol study results exceeded management’s expectations: • Permeation study of Sol demonstrates: • statistically significant greater dermal delivery compared with four known comparator products • confirmation of exceeding bioequivalence compared with oral delivery • Sensitisation
Slide 5: Financial Highlights
Financial Highlights • Strong financial control through period, financial position on track • Completion of the IPO subscription agreements realising £350k investment from an existing shareholder, the Board of directors and the management team • Cash balance at 30 September 2020 of £433k (2019: £51k
Slide 6: Company Heritage
Company Heritage • Incanthera was established as UK oncology focused, targeted drug development company originating form the Institute of Cancer Therapeutics, University of Bradford • Acquiring, preparing and commercialising new oncology technologies • Multiple asset portfolio • First commercial dea
Slide 7: Our Approach
Our Approach • Identify cutting edge technologies in oncology • Acquire intellectual property rights to product opportunities • Prepare technologies to valuation realisation • Commercialise through a partner, securing deal that aims to prioritise further development, marketing and early revenues to
Slide 8: Focus: Sol and the Skin Cancer Challenge
Focus: Sol and the Skin Cancer Challenge Skin cancer (including solar keratosis) is the UK SKIN CANCER RATES 2004-2016 most common form of cancer in white (NUMBERS PER 100,000) 30 populations, and deaths arising from invasive melanoma are on the increase. 25 • Solar Keratosis is a pre-cancerous area
Slide 9: Chief Executive's Review - Strategic Progress
Chief Executive’s Review -Strategic Progress Successful formulation work on Sol, our proprietary topical formulation to deliver into skin an active known to treat solar (actinic) keratoses and prevent formation of related skin cancers Formulators have delivered a concentration with statistically sig
Slide 10: Oncology Product Pipeline
Oncology Product Pipeline Acquisition Preparation for Licensing Licensing Platform Product Indication Skin cancers: Topical solar keratosis (SK), Market Sol Cream melanoma Bioequivalence Launch (SK - $3.4bn)* VDA Lung, breast, & ovarian cancers Pre-clinical Licensed to ($5.9bn, $15.3bn, Theranostic
Slide 11: Our Business Model
Our Business Model We have established a broad pipeline portfolio • Not reliant upon one single technology origin • A pipeline of product opportunities from various sources We develop our products with expertise, in preparation for commercialising • No requirement for the Company to run late-stage c
Slide 12: Financial Overview
Financial Overview Financial Performance • Strong financial control through period; financial position on track • Cash balance at 30 September 2020 of £433k (2019: £51k) • Operating losses for the period reduced to £471k (2019: £485k) Investment • Shareholder base offers support across institutional
Slide 13: Future Prospects
Future Prospects Confident of delivering further positive milestones in the near future Consistently reviewing new opportunities and the evolution of our technologies to address the concern and demands across healthcare Continue to work closely with Institute of Cancer Therapeutics (“ICT”) at the Un